Background: The recently discovered LRP protein has been shown to be involved in drug resistance and possibly in detoxification processes.
Introduction
Drug resistance is common in lung cancer. Although small-cell lung cancer (SCLC) is initially very sensitive to chemotherapy, it recurs in most cases, which are then resistant to multiple drugs. Non-SCLC (NSCLC) is relatively resistant to chemotherapy from diagnosis. Among known mechanisms of drug resistance, overexpression of the MDR1 gene, which encodes for P-glycoprotein, does not seem to play an important role in lung cancer [1, 2] .
Recently, a new resistance protein, called Lung Resistance-related Protein (LRP), has been identified in a lung cancer cell line selected for resistance to doxorubicin [3] . LRP is the major component of the human vaults [4, 5] and may be involved in transport mechanisms within the cell [6] . Overexpression of LRP was found in multi-drug resistant (MDR) cell lines not overexpressing the MDR1 gene [7] . LRP overexpression may involve cross-resistance to classical MDR drugs but also platinum agents [8] . LRP expression was found to have a predictive value for poor response to chemotherapy and adverse clinical outcome in advanced ovarian cancer and acute myeloid leukemia (AML) [8, 9] . The pattern of LRP expression in various normal tissues, similar to that of P-glycoprotein, suggests a role in detoxification processes [10] .
The LRP gene maps to the short arm of chromosome 16 proximal to the MDR-associated Protein MRP [11] . Although LRP and MRP may be co-upregulated, they can also be switched on independently [7, 11] . Evidence exists that chromosome breakage plays a role in LRP or MRP amplification [11] .
To elucidate the role of LRP in the detoxification process we estimated the LRP expression in lung tissues derived from non-cancer patients and related the expression to smoking of cigarettes. Furthermore the expression of LRP in lung tumor samples was evaluat-ed and compared with patients' survival, tumor differentiation, TNM classification and histology. Finally, the LRP and MRP protein expression was preliminary assessed in tumor samples derived from lung cancer patients who underwent chemotherapy and related to trie response to chemotherapy. 1:50. Negative controls were placed in PBS or treated with an irrelevant mouse myeloma IgGl antibody and the remaining samples were incubated with LRP-56 (1:500) for 1 hour, whereas the rest of the staining procedure was identical to the procedure described for the paraffin-embedded sections. The percentage of tumor cells which stained with the antibody was assessed independently by two ofus(PvdV.AMCD).
Materials and methods

Patients' material
Fifty peripheral lung tissue samples were analysed, derived from patients who underwent a bullectomy as treatment for pneumothorax. None of these patients had a history of cancer, and smoking habits of these patients were recorded. Pack years were calculated as the amount of cigarette packs smoked per day times the number of years smoked.
Tumor specimens of 36 patients with NSCLC were investigated; these patients were not treated with chemotherapy at any time and were operated on between 1987-1990. The median follow-up was 78 months (range 1-94 months).
Tumor samples of 17 patients (7 SCLC and 10 NSCLC) treated with chemotherapy were analysed for both LRP and MRP expression. These samples were derived from different tumor sites (primary tumor, mediastinal lymph nodes or supraclavicular lymph nodes). All these patients received chemotherapy before or after sampling the tumor tissues. Responses were evaluated by chest X-ray and/or CT-scan. Response was classified according to WHO criteria [12] . Expression of rumors of patients with a tumor reduction (i.e., minor, partial or complete response) after chemotherapy were compared to those that progressed.
All lung cancer samples were snap frozen in liquid nitrogen and stored at -80 'C until use. The bullectomy samples were embedded in paraffin and stored at room temperature.
MRP immunostaining
Cryostat sections of tumor samples were acetone fixed, preincubated with normal rabbit serum (1:50) for 15 minutes, followed by a 1 hour incubation with the rat MAb MRPrI [13] . Controls were treated as described in the LRP section. Peroxidase conjugated rabbitanti-rat immunoglobuline (1:25) + 2% human pool serum was applied for 1 hour. The bound peroxidase was developed by DAB incubations, slides were counterstained with hematoxilin, dehydrated and mounted. As positive control the human SCLC cell line GLC4/ADR 150 , known to overexpress MRP [14] , was used. Tumor cells staining with the MRP MAb was recorded as the percentage of positive tumor cells, as described for the LRP staining of frozen sections.
Statistics
Overall survival and disease-free survival were calculated in months from surgery until relapse or death. As cut-off point for KaplanMeier curves [15] , 10% LRP positive tumor cells was used. This cutoff point has been shown to efficiently distinguish between groups bearing different drug resistance profiles (10] . Comparisons of survival curves were performed by Mantel-Cox method [16] . KruskalWallis one-way nonparametric analysis of variance and MannWhitney rank sum test were used to compare protein expression levels in various groups.
LRP immunostaining
Formalin-fixed paraffin embedded normal lung tissues were cut into sections of 4 u. thickness. Sections were deparaffinized and rehydrated and slides were microwaved in a citrate buffer at pH 6.0 for 15 minutes, in order to avoid background staining. Endogenous peroxidase activity was blocked with H 2 O 2 in methanol, and all slides were incubated with normal rabbit serum (1:50). Controls were placed in phosphate buffered saline (PBS) or incubated with an irrelevant mouse myeloma IgGl antibody. The remaining slides of normal lung tissue were incubated overnight with the mouse monoclonal antibody (MAb) LRP-56 (IgG2b) (1:100) at 4*C. The avidin-biotin complex procedure was used with rabbit anti-mouse (1:500) and streptavidin-biotin horse radish peroxidase incubations. The slides were developed in 3,3'-diaminobenzidine tetrahydrochloride (DAB, Sigma Chemical Co., St Louis, MO), counterstained with hematoxilin, dehydrated and mounted with depex. As LRP is expressed in normal lung tissue [10] we did not determine the percentage of LRP positive epithelial cells, but the intensity of the LRP immunoreactivity. To exclude influence of external factors the intensity of LRP staining of the epithelial cells lining the bronchioli was compared to the intensity of the alveolar macrophages in the same section: a score of zero to three (no, weak, moderate, and intense staining, respectively) was given. Scores were given independently by two of us and agreement was reached in all cases after discussion of difficult cases. Groups with high and low LRP intensity were compared, cut-off point being the median level of expression.
Immunohistochemical staining (IHC) using the MAb LRP-56 was performed on 4 n frozen lung tumor sections, which were acetone fixed. The lung cancer cell line SW1573-2R120 served as positive control. All samples were preincubated for 10 minutes with normal rabbit serum (Sigma Chemical Co., St. Louis, MO) diluted-
Results
LRP in normal lung tissue
Of the 50 bullectomy sections only 39 contained one or more bronchioli which were further analysed. Mean age of these 39 patients was 33 years (range 18-72), and most patients were male (30/39). Twenty-five patients were current smokers and 5 gave up smoking. Mean number of pack years was 9.9 (range 0-50) in the 29 cases in which information was available. None of these patients had an a,anti-trypsine deficiency, and 2 patients suffered from asthma.
The lung tissue in general showed strong emphysematic changes and not much of the normal lung structure was left for histochemical assessment. The LRP intensity in the epithelial cells was low to moderate in most samples when compared to the intensity of adjacent alveolar macrophages: median LRP intensity was 1 ( Figure 1 ). Number of pack years was not significantly different when 2 groups of patients were distinguished based on the median level of LRP intensity. Patients were further divided into three groups according to smoking history: non-smokers, 1-10 pack years, and more than 10 pack years. No difference in LRP intensity was found between these groups (Figure 2) . 
LRP in tumor samples
Characteristics of the 36 resected NSCLC patients are described in Table 1 . In normal tissue, adjacent to the tumor, alveolar macrophages, epithelial cells lining the bronchus, and connective tissue also stained with the LRP antibody. LRP staining gave raise to a coarsely granular cytoplasmic staining, as previously described (Figure 1 ) [3] . IHC of the tumor sections showed different expression of LRP in the different histological subtypes of lung cancer ( Figure 3 ): NSCLC samples had a significant (P < 0.0001) higher LRP expression than 7 SCLC samples. Within the NSCLC group squamous cell carcinomas and adenocarcinomas showed a significantly (P < 0.05) higher expression than the large cell undifferentiated carcinomas, suggesting a relation between LRP and tumor differentiation. Two patients had a mixed adeno-squamous tumor, large parts of these tumors being undifferentiated; with regard to LRP expression these tumors were comparable to the large cell undifferentiated tumors and, no difference was seen in these tumors between LRP expression in the differentiated and the undifferentiated areas. Expression levels were not significantly different in different stages or in different tumor differentiation grades. No relation was seen between LRP expression and the survival of the patients ( Figure 4) ; however, patients with squamous cell carcinoma had a significant better survival than patients with adeno or mixed carcinomas (P < 0.05).
Expression of LRP and MRP and response to chemotherapy
Seventeen samples derived from patients treated with chemotherapy were analysed. All 7 SCLC patients were treated with combination chemotherapy including cyclophosphamide, doxorubicin and etoposide. The 10 NSCLC patients ah 1 received cisplatin-containing chemotherapy combined with either paclitaxel, etoposide or teniposide. Two patients who had a stage I SCLC were operated on and received adjuvant chemotherapy; these patients were in remission at last followup and were excluded from response analysis. In addi- 
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Pretreated with chemotherapy tion one NSCLC patient who died after receiving 1 cycle of chemotherapy due to toxicity was also excluded from response analysis. Four out of 14 patients included in the response analysis had a progressive disease, and the other 10 patients had a response to chemotherapy; no patient had stable disease.
LRP levels in the 7 SCLC samples were low (< 10% positive cells). None of the SCLC samples showed immunoreactivity with the MRP MAb. Although all NSCLC samples showed a high percentage of tumor cells staining with the LRP MAb (mean 75%, range 30%-100%) only 3 NSCLC samples expressed MRP. Out of these 3 samples only one tumor sample displayed the typical intense membranous MRP staining (Figure 1 ), whereas the other 2 had a less intense staining and more diffuse to the cytoplasm. No relation was seen between MRP and LRP protein levels. In this small and heterogeneous group of patients LRP and MRP levels in patients with a response to chemotherapy were not different from protein levels in patients with progressive disease.
Discussion
The recently discovered vaults are highly conserved organelles among different species, suggesting an essential role in the cell physiology [17] . The finding that part of the vault ribonucleoprotein particles specifically localise to the nuclear pore complex, suggests that LRP may be responsible for bidirectional nucleocytoplasmic transport [18] . Vaults were first discovered in cytoplasmic vesicles fractions, which is in agreement with the punctuate cytoplasmic staining pattern of LRP-56, and there is evidence that cytostatic drugs can be trapped into vesicles and transported through the cytoplasm, resulting in a reduced nuclear accumulation of the drug [19] . In human normal lung tissue high LRP expression is present in bronchial epithelial cells and in alveolar macrophages [10] .
Because the LRP distribution among normal tissues suggests a role in the detoxification process [10, 17] we investigated its expression in normal lung tissues. In this study we showed immunoreactivity with the LRP-56 MAb in the vast majority of normal lung tissues tested (34/39). The intensity of the LRP immunoreactivity varied among these samples but most samples expressed a lower amount of LRP in the epithelial cells lining the bronchioli than in the alveolar macrophages. No relation was seen between cigarette smoke and LRP expression, but there was a trend for higher expression levels in patients who had smoked more than 10 pack years compared with the patients who never smoked. However, the pneumothorax patients are not age-matched with the lung cancer patients, who are older, have a higher frequency of smoking history, and have a longer exposure to smoke. In our series, from 19 of 36 NSCLC patients from whom data were available on smoking history, the mean number of pack years smoked was 38 (range 0-100), and only one patient had never smoked cigarettes.
Experiments in cell lines selected for resistance to several drugs have shown LRP expression in low level of drug resistance [3] , as an early event in the selection for resistance to several MDR related drugs. LRP expression level drops in cells with a higher resistance level where Pgp expression emerges. High expression levels of LRP were seen in our study in NSCLC, as only 5 out of 36 NSCLC samples were negative, independent of TNM-classification or tumor differentiation. This was in contrast to 100% negativity in 7 SCLC samples, independent of pretreatment or response to chemotherapy. It is known that highly chemosensitive tumors (i.e., testicular cancer, Wilm's tumor, leukemias and SCLC) show low LRP expression [10] .
LRP and MRP expression was found in 87% and 78% of unselected cell lines respectively [7] , suggesting that both proteins can be involved in the intrinsic drug resistance and not only in the acquired drug resistance as a response to previous chemotherapy. In contrast to studies in advanced ovarian cancer and AML [8, 9] , in 36 NSCLC with long term follow-up the level of LRP expression was not a prognostic factor for survival. As the prognosis of AML and advanced ovarian cancer is tightly linked to the response to chemotherapy, it is likely that LRP influences response to chemotherapy in AML and ovarian cancer, and secondarily survival. Whether LRP as P-glycoprotein could also be a sign of tumor aggressiveness is still unclear [20] , but it is not likely to be the case in our NSCLC series.
In our study no relation was seen between LRP expression and response to chemotherapy. Expression levels in all SCLC samples were very low, independent of response and previous exposure to chemotherapy. Although all 3 NSCLC with progressive disease displayed more than 85% LRP expression, expression levels were not significantly different from the 6 NSCLC patients who responded to chemotherapy. A study in melanoma showed a significant correlation between increase in LRP expression levels and pretreatment with chemotherapy [21] . Our results, however, should still be considered preliminary, because of the relatively small number of patients.
In a recent study MRP mRNA expression assessed by RNase protection assay was detectable in all NSCLC tumor samples and adjacent normal lung tissues tested [22] . Moreover, Ota et al. evaluated the MRP and MDRl transcript in 104 NSCLC samples by Northern blot analysis and semi-quantitative reversetranscriptase polymerase chain reaction [23] . Patients with a high MRP expressing tumor showed a significantly worse prognosis than patients with a no or low MRP expressing tumor. However, MRP protein expression is present in non-neoplastic cells infiltrating the tumor [22] , making unreliable the results obtained by bulk techniques. In our series only 3 samples out of 17 samples tested were positive for MRP by IHC, 2 of which were derived from pretreated patients. Nevertheless, all three patients with MRP-overexpressing tumors achieved a response to cisplatin-etoposide-containing chemotherapy. In unselected human lung cancer cell lines only a modest association was observed between MRP mRNA levels and chemosensitivity to doxorubicin and etoposide, but not to cisplatin [22] .
Clinical drug resistance is likely to be multifactorial: in addition to drug transport mechanisms DNA topoisomerases and the glutathione system may be involved in drug resistance [24] [25] [26] .
In conclusion, although we did not find a relation between LRP intensity and the level of smoke exposure, higher LRP intensity levels tended to be related with an increased load of cigarette smoke as was observed in lung cancer patients. LRP expression in SCLC was significantly lower than in NSCLC samples, and did not seem to play a role in drug resistance in a relatively small group of lung cancer patients treated with chemotherapy.
